clofibric acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 695 | 882-09-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 45 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 5.70 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 155.14 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1963 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000924 | Anticholesteremic Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000960 | Hypolipidemic Agents |
| MeSH PA | D057847 | Lipid Regulating Agents |
| CHEBI has role | CHEBI:24527 | herbicides |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:35679 | antilipemic drugs |
| CHEBI has role | CHEBI:35821 | anticholesteremic drugs |
| CHEBI has role | CHEBI:70782 | PPAR-alpha agonist |
| CHEBI has role | CHEBI:83399 | marine xenobiotic metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.71 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Lipoprotein lipase | Enzyme | WOMBAT-PK | |||||||
| Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | EC50 | 4.40 | CHEMBL | |||||
| Peroxisome proliferator-activated receptor alpha | Transcription factor | EC50 | 7.38 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07723 | KEGG_DRUG |
| C0009003 | UMLSCUI |
| CHEBI:34648 | CHEBI |
| CHEMBL683 | ChEMBL_ID |
| D002995 | MESH_DESCRIPTOR_UI |
| 2797 | PUBCHEM_CID |
| 2439 | INN_ID |
| 53PF01Q249 | UNII |
| E0O | PDB_CHEM_ID |
| DB13780 | DRUGBANK_ID |
Pharmaceutical products:
None